Five9 Inc vs Revvity Inc — how do they compare? Five9 Inc trades at $36.4 (market cap $2.63B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 6.5× Five9 Inc's market cap, and Revvity Inc pays a 0.18% dividend while Five9 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Revvity Inc for 12 Days on average.
| FIVN | RVTY | |
|---|---|---|
Market Cap | $2.63B | $16.98B |
Volume | 1,864,393 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $38.65 | $157.36 |
52-Week Low | $13.61 | $82.26 |
Typical Hold Time | 72 Days | 12 Days |
Enterprise Value | $2.78B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) is trading at $35.15, up 4.06% with strong technical momentum and bullish moving average signals. The company shows accelerating revenue growth, reaching $1.15B in 2025 with improving profitability as net income turned positive at $39.42M. Recent quarterly earnings consistently beat expectations, while AI revenue surged 78% YoY to $39M in Q2 2026. The stock trades near resistance at $35 with solid institutional support despite recent insider selling activity.
FIVN presents growth potential driven by AI contact center adoption and subscription revenue expansion, but faces valuation concerns with a 51.69 P/E ratio. Key risks include competitive pressure in CCaaS markets and execution challenges in maintaining current growth trajectory. Analyst consensus remains bullish with 61% buy ratings and $34 price target, though current price exceeds consensus target.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →